InnoCare Pharma Ltd
SSE:688428

Watchlist Manager
InnoCare Pharma Ltd Logo
InnoCare Pharma Ltd
SSE:688428
Watchlist
Price: 24.93 CNY -1.5% Market Closed
Market Cap: 21B CNY

Wall Street
Price Targets

Price Targets Summary
InnoCare Pharma Ltd

Wall Street analysts forecast InnoCare Pharma Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 24.91 CNY with a low forecast of 23.33 CNY and a high forecast of 27.03 CNY.

Lowest
Price Target
23.33 CNY
6% Downside
Average
Price Target
24.91 CNY
0% Downside
Highest
Price Target
27.03 CNY
8% Upside
InnoCare Pharma Ltd Competitors:
Price Targets
ZNTL
Zentalis Pharmaceuticals Inc
298% Upside
4893
Noile-Immune Biotech Inc
164% Upside
BVXP
Bioventix PLC
72% Upside
BONEX
Bonesupport Holding AB
67% Upside
ALT
Altimmune Inc
224% Upside
688382
InventisBio Co Ltd
13% Downside
BIOCON
Biocon Ltd
14% Upside
IMMX
Immix Biopharma Inc
213% Upside

Revenue
Forecast

Revenue Estimate
InnoCare Pharma Ltd

For the last 3 years the compound annual growth rate for InnoCare Pharma Ltd's revenue is -1%. The projected CAGR for the next 3 years is 33%.

-1%
Past Growth
33%
Estimated Growth
Estimates Accuracy
0%
Average Miss

Operating Income
Forecast

Operating Income Estimate
InnoCare Pharma Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Net Income
Forecast

Net Income Estimate
InnoCare Pharma Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is InnoCare Pharma Ltd's stock price target?
Price Target
24.91 CNY

According to Wall Street analysts, the average 1-year price target for InnoCare Pharma Ltd is 24.91 CNY with a low forecast of 23.33 CNY and a high forecast of 27.03 CNY.

What is InnoCare Pharma Ltd's Revenue forecast?
Projected CAGR
33%

For the last 3 years the compound annual growth rate for InnoCare Pharma Ltd's revenue is -1%. The projected CAGR for the next 3 years is 33%.

Back to Top